Literature DB >> 32589727

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Brian J Ball1, Christopher A Famulare2, Eytan M Stein1, Martin S Tallman1, Andriy Derkach3, Mikhail Roshal1, Saar I Gill4, Benjamin M Manning4, Jamie Koprivnikar5, James McCloskey5, Rebecca Testi5, Thomas Prebet6, Najla H Al Ali7, Eric Padron7, David A Sallman7, Rami S Komrokji7, Aaron D Goldberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32589727      PMCID： PMC7362378          DOI： 10.1182/bloodadvances.2020001482

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

1.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.

Authors:  J E Parker; G J Mufti; F Rasool; A Mijovic; S Devereux; A Pagliuca
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors:  S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

3.  Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.

Authors:  Bartlomiej M Getta; Sean M Devlin; Ross L Levine; Maria E Arcila; Abhinita S Mohanty; Ahmet Zehir; Martin S Tallman; Sergio A Giralt; Mikhail Roshal
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-15       Impact factor: 5.742

4.  Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Authors:  Ibrahim Aldoss; Jianying Zhang; Raju Pillai; Geoffrey Shouse; James F Sanchez; Matthew Mei; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Br J Haematol       Date:  2019-08-22       Impact factor: 6.998

5.  Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Sylvain Thépot; Benjamin Esterni; Bruno Quesnel; Odile Beyne Rauzy; François Dreyfus; Claude Gardin; Pierre Fenaux; Norbert Vey
Journal:  Br J Haematol       Date:  2012-03-06       Impact factor: 6.998

6.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien; Jorge Cortes; Farhad Ravandi; Jean-Pierre Issa; Hagop Kantarjian
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

7.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

8.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

9.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

10.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
View more
  12 in total

Review 1.  The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

Authors:  Sarah T Diepstraten; Mary Ann Anderson; Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Gemma L Kelly
Journal:  Nat Rev Cancer       Date:  2021-10-18       Impact factor: 60.716

Review 2.  Oncology stewardship in acute myeloid leukemia.

Authors:  Madeleine A Ochs; Bernard L Marini; Anthony J Perissinotti; Charles E Foucar; Kristen Pettit; Patrick Burke; Dale L Bixby; Lydia L Benitez
Journal:  Ann Hematol       Date:  2022-05-26       Impact factor: 4.030

Review 3.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

Review 4.  Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.

Authors:  Naseema Gangat; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2020-11-23       Impact factor: 11.037

5.  Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.

Authors:  Jonathan Feld; Douglas Tremblay; Mikaela Dougherty; Tina Czaplinska; Gillian Sanchez; Claudia Brady; Marina Kremyanskaya; Michal Bar-Natan; Alla Keyzner; Bridget K Marcellino; Janice Gabrilove; Shyamala C Navada; Lewis R Silverman; Siraj M El Jamal; John Mascarenhas; Alan H Shih
Journal:  Hemasphere       Date:  2021-03-09

6.  Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.

Authors:  Xiao Li; Feng Xu; Zheng Zhang; Juan Guo; Qi He; Lu-Xi Song; Dong Wu; Li-Yu Zhou; Ji-Ying Su; Chao Xiao; Chun-Kang Chang; Ling-Yun Wu
Journal:  Clin Epigenetics       Date:  2021-08-30       Impact factor: 6.551

7.  Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.

Authors:  Nicholas J Short; Sangeetha Venugopal; Wei Qiao; Tapan M Kadia; Farhad Ravandi; Walid Macaron; Courtney D Dinardo; Naval Daver; Marina Konopleva; Gautam Borthakur; Elizabeth J Shpall; Uday Popat; Richard E Champlin; Rohtesh Mehta; Gheath Al-Atrash; Betul Oran; Elias Jabbour; Guillermo Garcia-Manero; Ghayas C Issa; Guillermo Montalban-Bravo; Musa Yilmaz; Abhishek Maiti; Hagop Kantarjian
Journal:  J Hematol Oncol       Date:  2022-01-29       Impact factor: 17.388

8.  The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.

Authors:  Istemi Serin; Mehmet Hilmi Dogu
Journal:  Int J Hematol Oncol       Date:  2021-11-12

Review 9.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

Review 10.  PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Christina-Nefeli Kontandreopoulou; Panagiotis T Diamantopoulos; Despina Tiblalexi; Nefeli Giannakopoulou; Nora-Athina Viniou
Journal:  Blood Adv       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.